Nasdaq:US$13.64 (-0.17) | HKEX:HK$20.75 (-0.30) | AIM:£2.19 (-0.08)
News & Presentations
Previous Article   |   Next Article
Presentations | 22 Jan 2022

ASCO GI 2022 | Phase 1/1b trial of fruquintinib in patients with advanced solid tumors: preliminary results of the dose expansion cohorts in refractory metastatic colorectal cancer